Protagonist Therapeutics, Inc. (PTGX)
NasdaqGM · USD · Healthcare · Biotechnology
$140.32 (+1.37%) as of
Key statistics
- Market cap
- 9.08B
- P/E (TTM)
- 136.23
- Forward P/E
- -1,413.66
- EPS (TTM)
- 1.03
- Dividend yield
- 0.00%
- 52-week range
- 74.03 – 160.81
- Beta
- 1.52
- Revenue (TTM)
- 281.99M
- Profit margin
- 29.40%
- Analyst target
- $178.57
- Volume
- 819.31k
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Newark, CA, United States
- Employees
- 141
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.